For research and educational purposes only. This page is a factual research reference, not medical advice. Any dosing figures shown are amounts reported in the research literature, provided for educational context — not instructions or recommendations for human use.
Overview
ELIXA examined lixisenatide in people with type 2 diabetes who had recently experienced an acute coronary event. It offers an important example of why cardiovascular findings cannot be assumed to apply to every GLP-1 compound.
At a glance
ClassGLP-1 receptor agonist
CategoryGLP-1 Family
Page purposeResearch and educational reference
Regulatory statusThis page summarizes the cited research. Regulatory authorization is specific to a product, indication and jurisdiction; consult the relevant regulator for current labeling.
Selected evidence, in context
A closer reading of selected linked publications. This is not a systematic review, an evidence grade or a complete account of safety and effectiveness.
6,068 people with type 2 diabetes and a recent acute coronary event; median follow-up 25 months
Research question
Did adding lixisenatide to usual care change the composite cardiovascular-event rate?
Reported finding
The primary-event hazard ratio was 1.02 (95% CI 0.89–1.17). Lixisenatide met the prespecified noninferiority criterion but did not demonstrate superiority to placebo.
What this cannot establish
Noninferiority is not proof of cardiovascular benefit or zero risk. The finding concerns patients with recent acute coronary syndrome receiving usual care.
Lixisenatide engages the GLP-1 receptor; ELIXA evaluated clinical outcomes rather than establishing a new receptor mechanism.
Mechanistic description reflects published research-literature understanding. Much peptide research is preclinical (in-vitro or animal-model); mechanism in humans may differ and is not established for many compounds.
What it's studied for
Research contexts in which Lixisenatide appears in the literature. Listing a research area is not a claim of efficacy or a therapeutic indication.
Type 2 diabetesCardiovascular outcomes
Key characteristics
The trial did not demonstrate a significant change in major cardiovascular events compared with placebo. This is different from demonstrating cardiovascular benefit.
How it compares
The trial did not demonstrate a significant change in major cardiovascular events compared with placebo. This is different from demonstrating cardiovascular benefit.
Commonly studied alongside
Compounds frequently researched together with Lixisenatide in the literature. Cross-referenced for research context — not a usage or combination recommendation.
Side-by-side pages for the pairings the literature already documents for Lixisenatide, plus the unit-conversion reference for a reconstituted vial. Factual comparisons of documented characteristics — not a recommendation to combine or use any compound.
The trial did not demonstrate a significant change in major cardiovascular events compared with placebo. This is different from demonstrating cardiovascular benefit.
Does this reference establish that a supplier product is equivalent?
No. A study of a defined pharmaceutical formulation does not verify the identity, purity, sterility or clinical suitability of any separately sold material.
Publications indexed in PubMed and linked to this profile, including original studies and reviews. Publication labels reflect PubMed indexing, not evidence strength. Listing a study records that it exists and is indexed — it is not a claim of efficacy, a therapeutic indication, or an endorsement of its conclusions. Much of this literature is preclinical (in-vitro or animal-model).
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome N Engl J Med, 2015. PubMed 26630143
Bibliographic metadata refreshed from PubMed on 2026-09-20. This checks the record identity and metadata; it is not a new review of every scientific claim. A reference may concern a related molecule or formulation: read its methods and the context above. See the editorial policy.
